Iakovos Toumazis, Ph.D.
Department of Health Services Research, Division of Cancer Prevention and Population Sciences
Present Title & Affiliation
Primary Appointment
Adjunct Assistant Professor, Department of Computational Applied Mathematics & Operations Research, Division of Cancer Prevention and Population Sciences, Rice University, TX
Assistant Professor, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | University of Buffalo, SUNY, Buffalo, New York, US, Ph.D. in Industrial Engineering |
| 2012 | University of Buffalo, SUNY, Buffalo, New York, US, M.S. in Industrial Engineering |
| 2009 | University of Patras, Patras, GR, BS in Mathematics |
Postgraduate Training
| 2015-2020 | Postdoctoral Research Fellow, Stanford University, Stanford, California |
Experience & Service
Other Professional Positions
Institute for Data Science in Oncology (IDSO) Affiliate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present
Graduate Assistant, Industrial Engineering, Goodwill Industries of Western New York, Buffalo, NY, 2011 - 2012
Institutional Committee Activities
Member, MedTech Innovation Council, 2024 - Present
Committee Member, PhD thesis committee, 2024 - Present
Member, Forecasting and Decision Sciences for the Health of Individuals and Societies, 2024 - 2024
Member, CCSG Gyn Cancers Program Retreat, 2023 - 2024
Member, Department of Health Services Research, 2023 - Present
Member, DCPPS Employee Recognition Awards Review Board, 2022
Member, Department of Epidemiology, 2022 - Present
Member, Lung Cancer Early Detection Working Group, 2021 - Present
Member, Internal Advisory Board for the Shared Decision Making Core, MDACC Cancer Center Support Grant (CCSG), 2021 - Present
Member, Lung Cancer Screening Task Force, 2021 - Present
Member, Integrative Biomedical Imagine Informatics at Stanford (IBIIS) Annual Retreat Organizing Committee, 2018
Honors & Awards
| 2025 | Finalist in the Lee B. Lusted Student Prize Competition at the 47th Annual Meeting of the Society for Medical Decision Making, Society for Medical Decision Making |
| 2018 | Best Poster Award, Integrative Biomedical Imagine Informatics at Stanford (IBIIS) Annual Retreat, Stanford University |
| 2015 | Institute of industrial Engineers Doctor Colloquium, Institute of industrial Engineers |
| 2015 | Winner of the Society for Health Systems Best Graduate Student Paper Competition, Institute of industrial Engineers |
| 2012 | University Transportation Research Center (UTRC) Travel Award, University Transportation Research Center (UTRC) |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Decision Analytic model for indeterminate findings. Invited. ENGAGE Annual Meeting. Houston, Texas, US.
- 2025. Integrating non-smoking related risk factors into ENGAGE. Invited. ENGAGE Annual Meeting. Houston, Texas, US.
- 2024. Trends in Family History of Lung Cancer & Competing Comorbidities. Invited. ENGAGE Annual Meeting. Houston, Texas, US.
- 2024. Calibration of Histology-Specific Natural History Models for Ovarian Cancer Using Simulated Annealing Algorithm. Poster. CCSG Gynecologic Oncology Cancer Retreat. Houston, TX, US.
- 2024. Evaluation of Refined PLCOm2012 Models for ENGAGE in Mexican American Smokers using Mano-a-Mano Cohort. Invited. ENGAGE Annual Meeting. Houston, Texas, US.
- 2023. The Impact of Practicality on the Effectiveness and Efficiency of Lung Cancer Screening Programs. Invited. EDRN Site Meeting. Houston, Texas, US.
- 2023. Personalized Lung Cancer Screening: Project Engage. Invited. Health Services Research Seminar Series. Houston, TX, US.
- 2023. Personalized Lung Cancer Screening: The ENGAGE Framework. Invited. 2023 EDRN Lung CVC Meeting. Houston, TX, US.
- 2023. Development of an Ovarian Cancer Risk Prediction Model. Conference. Cancer Center Support Grant (CCSG). Houston, Texas, US.
- 2022. Informing Lung Cancer Screening Policy Using Decision-Analytic Models. Invited. Cancer Prevention and Control Grand Rounds. Houston, TX, US.
- 2022. Personalized Lung Cancer Screening Acceptability among Primary Care Providers. Poster. MD Anderson Summer Experience Final Exposition. Houston, Texas, US.
- 2022. Personalized Lung Cancer Screening Acceptability among Primary Care Providers. Poster. Cancer Prevention Research Training Program Summer Trainee Exposition. Houston, Texas, US.
Regional Presentations
- 2025. Panel discussion for consensus recommendations. Panelist. Occupational Flight Exposure and Cancer Risk Symposium. Houston, TX, US.
National Presentations
- 2025. Updates from the ENGAGE Framework. Invited. 2025 CISNET Mid-Year Meeting, US.
- 2024. Predicting lung cancer risk with CT radiomics: implications for immunoprevention. Poster. Society for Immunotherapy of Cancer's 39th Annual Meeting 2024. Houston, TX, US.
- 2024. The ENGAGE Framework: Personalizing Lung Cancer Screening. Invited. 2024 CISNET Mid-Year Meeting. Rockville, Maryland, US.
- 2023. The ENGAGE Framework (Revisited). Invited. 2023 CISNET Annual Meeting. Rockville, Maryland, US.
- 2023. A four-protein blood biomarker panel refines a clinical risk score for indeterminate pulmonary nodules. Poster. EDRN Scientific Workshop. Gaithersburg, MD, US.
- 2023. The ENGAGE Framework; The impact of screening structure on the performance of lung cancer screening. Invited. 2023 CISNET Mid-Year Meeting. Seattle, WA, US.
- 2023. Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival. Poster. 2023 ASCO Annual Meeting. Chicago, IL, US.
- 2023. Disparities in uptake of levonorgestrel-releasing intrauterine system (LNG-IUS): implications for uterine cancer primary prevention. Conference. 2023 AACR Annual Meeting. Orlando, FL, US.
- 2023. Lung cancer screening status and acceptability of a personalized approach in Texas. Conference. 2023 ASCO Annual Meeting. Chicago, IL, US.
- 2022. Impact of Adherence on the Cost-Effectiveness of the Lung Cancer Screening Program: An exploratory analysis,. Invited. 2022 CISNET Annual Meeting. Virtual, US.
- 2021. Cost-Effectiveness Analysis of Risk-Based Lung Cancer Screening. Invited. 2021 CISNET Annual Meeting. Virtual, US.
- 2021. Personalizing Lung Cancer Screening Using a Decision-Analytic Model: Insights from the ENGAGE Framework,. Invited. 2021 CISNET Mid-Year Meeting. Virtual, US.
- 2020. Personalized Adaptive Lung Cancer Screening: Insights from the ILungSS framework. Invited. 2020 CISNET Annual Meeting. Rockville, MD, US.
- 2020. Cost-Effectiveness of Risk-Based Lung Cancer Screening. Invited. 2020 CISNET Mid-Year Meeting. Virtual, US.
- 2019. Insights from a fully dynamic screening framework. Invited. 2019 CISNET Annual Meeting. Rockville, MD, US.
- 2019. Model Accessibility. Invited. 2019 CISNET Mid-Year Meeting. Seattle, WA, US.
- 2018. Personalizing Lung Cancer Screening Using a Partially Observable Markov Decision Process (POMDP). Invited. 2018 CISNET Annual Meeting. Rockville, MD, US.
- 2018. Cost-Effectiveness of Lung Cancer Screening Supplemented by a Hypothetical Diagnostic Biomarker. Invited. 2018 CISNET Annual Meeting. Rockville, MD, US.
- 2015. Assessing the role of sequencing up to three lines of chemotherapy in metastatic colorectal cancer treatment: A cost-effectiveness analysis. Conference. The 37th Annual Meeting of the Society of Medical Decision Making. St.Louis, Missouri, US.
- 2015. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. 2015 Healthcare Systems Process Improvement Conference. Orlando, FL, US.
- 2015. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. 2015 IIE Annual Conference. Nashville, TN, US.
- 2014. Eliciting cholesterol management guidelines' valuation of future life. Conference. The 36th Annual Meeting of the Society for Medical Decision Making. Miami, FL, US.
International Presentations
- 2025. Risk of Second Primary Lung Cancer Among Cancer Survivors Stratified by the Site of First Primary Cancer and Lung Cancer Screening Eligibility. Poster. 2025 ICSN Conference. Aarhus, DK.
- 2025. Integrating non-smoking risk factors into the ENGAGE framework: examining the impact of race/ethnicity on optimal lung cancer screening schedules. Poster. 2025 ICSN Conference. Aarhus, DK.
- 2025. Second Primary Lung Cancer Risk Among Cancer Survivors Stratified by First Cancer and Screening Eligibility. Poster. 2025 SMDM Annual Meeting. Ann Arbor, US.
- 2025. Integrating non-smoking risk factors into ENGAGE: Impact of race/ethnicity on lung cancer screening schedules. Conference. 2025 SMDM Annual Meeting. Ann Arbor, US.
- 2025. Histology-Specific Natural History Models of Ovarian Cancer. Poster. 2025 SMDM Annual Meeting. Ann Arbor, US.
- 2025. Drivers of Multi-Cancer Detection Test Cost-Effectiveness: A flexible cohort model for 16 cancer types. Poster. 2025 SMDM Annual Meeting. Ann Arbor, US.
- 2025. EE71: Cost-Effectiveness of Intensity-Modulated Proton Therapy (IMPT) for the Treatment of Head and Neck Oropharyngeal Carcinoma. Poster. 2025 ISPOR Annual Meeting. Montreal, CA.
- 2025. Cost-effectiveness analysis of the addition of metastasis directed therapy to intermittent hormone therapy for oligometastatic prostate cancer. Poster. 2025 American College of Radiation Oncology (ACRO) annual conference. Las Vegas, US.
- 2024. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. Conference. 2024 INFORMS Annual Meeting. Seattle, US.
- 2024. Calibration of Histology Specific Natural History Models for Ovarian Cancer Using Simulated Annealing. Conference. 2024 INFORMS Annual Meeting. Seattle, US.
- 2024. A four-protein blood biomarker panel refines a clinical risk score for indeterminate pulmonary nodules. Conference. American Thoracic Society International Meeting. San Diego, US.
- 2024. Lung Cancer Screening Eligibility and Use in the US: A Cross-Sectional Analysis of 2022 Behavioral Risk Factor Surveillance System Data. Poster. ISPOR 2024 international conference. Atlanta, US.
- 2024. Opportunistic Salpingectomy During Gynecologic and Non-Gynecologic Abdominopelvic Procedures for Ovarian Cancer Primary Prevention: A Cost-Effectiveness Analysis. Conference. Society of Gynecologic Oncology 2024 Annual Meeting. San Diego, US.
- 2023. Optimizing Lung Cancer Screening Schedules at the Individual-Level Using an Expanded Version of Engage, a Personalized Screening Decision Tool. Conference. INFORMS Healthcare 2023. Toronto, CA.
- 2023. The Impact of Practicality on the Effectiveness and Efficiency of Lung Cancer Screening Programs. Conference. INFORMS Healthcare 2023. Toronto, CA.
- 2023. Lung cancer screening among non-eligible Head and Neck cancer patients based on the 2021 US Preventive Services Task Force eligibility criteria. Conference. International Cancer Screening Network (ICSN) Meeting. Turin, IT.
- 2023. The Impact of Practicality on the Effectiveness and Efficiency of Lung Cancer Screening Programs. Conference. International Cancer Screening Network (ICSN) Meeting. Turin, IT.
- 2023. Disparities in Levonorgestrel-Releasing Intrauterine System Use (LNG-IUS) among American Women: Implications for Endometrial Cancer Prevention. Conference. American Association for Cancer Research (AACR) Annual Meeting. Orlando, US.
- 2023. Assessing the Loss in Effectiveness and Efficiency of Lung Cancer Screening by Enforcing a Structure on the Screening Policy. Conference. 2023 INFORMS Annual Meeting. Phoenix, US.
- 2023. Development of an Ovarian Cancer Risk Prediction Model. Conference. 2023 INFORMS Annual Meeting. Phoenix, US.
- 2023. The ENGAGE Framework for Personalizing Lung Cancer Screening. Conference. 2023 INFORMS Annual Meeting. Phoenix, US.
- 2022. The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program. Poster. World Conference on Lung Cancer. Vienna, AT.
- 2021. Accounting for Racial Differences in Optimizing Lung Cancer Screening Schedules. Conference. INFORMS Healthcare Meeting, Virtual Meeting, US.
- 2021. Personalized optimal lung cancer screening schedules: Study of implementable strategies via enforcing policy structure. Conference. 2021 INFORMS Annual Meeting. Anaheim, US.
- 2021. Evaluation of alternative diagnostic test intervals and thresholds for Lung-RADS criteria on the effectiveness of lung cancer screening. Conference. 2021 World Conference on Lung Cancer. Virtual, US.
- 2019. Personalized lung cancer screening strategies using a partially observable Markov decision process. Conference. 2019 INFORMS Healthcare Meeting. Cambridge, US.
- 2019. Individualized Risk-Based Lung Cancer Screening Incorporating Past Screening Findings and Changes in Smoking Behaviors. Poster. World Conference on Lung Cancer. Barcelona, ES.
- 2019. Evaluation of Alternative Subsequent Screening for LungRADS Criteria on the Effectiveness of Lung Cancer Screening. Conference. 2019 INFORMS Healthcare Meeting. Cambridge, US.
- 2019. Disparities and National Lung Cancer Screening Guidelines in the U.S. Population. Conference. World Conference on Lung Cancer. Barcelona, ES.
- 2018. Personalized lung cancer screening strategies using a partially observable Markov decision process. Conference. 2018 INFORMS Annual Meeting. Phoenix, US.
- 2018. Evaluation of alternative diagnostic test intervals and thresholds for Lung-RADS criteria on the effectiveness of lung cancer screening. Conference. 2018 INFORMS Annual Meeting. Phoenix, US.
- 2018. The effect of indeterminate findings on the cost-effectiveness of lung cancer screening. Conference. 2018 INFORMS Annual Meeting. Phoenix, US.
- 2017. Impact Of False-Positives On The Cost-effectiveness of Lung Cancer Screening. Conference. 2017 INFORMS Healthcare Conference. Rotterdam, NL.
- 2016. Evaluating the impact of diagnostic biomarkers on the cost-effectiveness efficiency frontier of alternative lung cancer screening strategies. Conference. 2016 INFORMS International Conference. Hawaii, US.
- 2016. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. 2016 INFORMS International Conference. Hawaii, US.
- 2016. Impact Of False-Positives On The Cost-effectiveness of Lung Cancer Screening. Conference. 2016 INFORMS Annual Meeting. Houston, US.
- 2015. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. 2015 INFORMS Annual Meeting. Philadelphia, US.
- 2015. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. 2015 MSOM Healthcare Special Interest Group Meeting. Toronto, CA.
- 2014. Eliciting cholesterol management guidelines' valuation of future life. Conference. 2014 INFORMS Annual Meeting. San Francisco, US.
- 2013. Advanced risk measures applied in hazardous materials routing. Conference. 2013 INFORMS Annual Meeting. Minneaspolis, US.
- 2012. Conditional value-at-risk for hazardous materials transportation on time-dependent networks. Conference. 2012 CORS-SCRO. Niagara Falls, ON, CA.
- 2012. Conditional value-at-risk for hazardous materials transportation on time-dependent networks. Conference. 2012 INFORMS Annual Meeting. Phoenix, US.
- 2012. Conditional value-at-risk for hazardous materials transportation on time-dependent networks. Conference. 2012 IIE Annual Conference. Orlando, US.
- 2011. Worst case conditional value-at-risk minimization in hazardous materials transportation. Conference. 2011 INFORMS Annual Meeting. Charlotte, US.
Formal Peers
- 2023. Optimization of Lung Cancer Screening Using Principles from Operations Research. Dallas, Texas, US.
- 2023. Applications of mathematical models in the context of lung cancer screening. Invited. Houston, TX, US.
- 2023. Changing the paradigm of lung cancer prevention using mathematical models, CyBioS Mini Symposium 2023 CancerNow: From Benchside to Clinical Applications. Invited, CY.
- 2021. Personalizing Lung Cancer Screening Using a Decision-Analytic Model: Insights from the ENGAGE Framework, ClubMeth Seminar Series. Invited, US.
- 2019. The Future of Lung Cancer Screening: Is Personalized Screening Necessary and Feasible?. Invited. Rockville, MD, US.
- 2019. Personalized Lung Cancer Screening: The Individualized Lung Screening Scheduler (ILungSS). Invited. Seattle, WA, US.
- 2019. Lung Cancer Screening: Is Individualized Screening a Feasible Solution to Existing Problems?. Invited. Houston, TX, US.
- 2019. A New Paradigm in Lung Cancer Screening: Screening for Individuals not Populations. Invited. Buffalo, NY, US.
- 2018. Personalizing Lung Cancer Screening Using a Partially Observable Markov Decision Process. Invited. Stanford, CA, US.
Grant & Contract Support
| Date: | 2026 - 2029 |
| Title: | Risk Based Ovarian Cancer Primay Prevention |
| Funding Source: | AMERICAN CANCER SOCIETY, NATIONAL |
| Role: | Mentor |
| ID: | FP00026802 |
| Date: | 2026 - 2030 |
| Title: | Multiplying Impact: Enhancing Lung Cancer Screening Programs with Integrated COPD Management |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Consult |
| Date: | 2026 - 2027 |
| Title: | Evaluation of a Risk-Based Ovarian Cancer Screening Program |
| Funding Source: | The Honorable Tina Brozman Foundation (“Tina’s Wish”) |
| Role: | PI |
| Date: | 2026 - 2028 |
| Title: | Widespread adoption of salpingectomy for ovarian cancer primary prevention |
| Funding Source: | Ovarian Cancer Research Alliance (OCRA) |
| Role: | PI |
| ID: | Grant--CRDG-2026-3-2364 |
| Date: | 2025 - 2029 |
| Title: | Family-based Helicobacter pylori screening and eradication for prevention of gastric cancer |
| Funding Source: | Baylor College of Medicine |
| Role: | PI |
| ID: | FP00022882 |
| Date: | 2025 - Present |
| Title: | Janice Davis Gordon Memorial Postdoctoral Fellowship in Colorectal Cancer Prevention |
| Funding Source: | Cancer Prevention Research Training Program (CPRTP) |
| Role: | Mentor |
| ID: | Cancer Prevention Research Training Program (CPRTP) |
| Date: | 2025 - 2030 |
| Title: | Predicting and enhancing lung cancer screening adherence using a decision-analytic framework |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PI |
| ID: | FP00024095 |
| Date: | 2025 - 2030 |
| Title: | Risks and Benefits of Long-Term Osteoporosis Therapy in Women with Breast Cancer |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PI |
| ID: | FP00024044 |
| Date: | 2025 - Present |
| Title: | Optimizing ovarian cancer early detection using mathematical modeling |
| Funding Source: | FOUNDATION FOR WOMENS CANCER |
| Role: | Mentor |
| ID: | FP00024760 |
| Date: | 2025 - 2030 |
| Title: | A decision-analytic framework to optimize ovarian cancer primary prevention at the individual-level |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PI |
| ID: | FP00022969 |
| Date: | 2025 - Present |
| Title: | Development of a shared decision tool to facilitate uptake of the levonorgestrel intrauterine device for primary prevention of endometrial cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP250293 |
| Date: | 2025 - 2029 |
| Title: | Optimizing reminders for lung cancer screening at the patient-level |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | FP00022808 |
| Date: | 2025 - Present |
| Title: | Lung Cancer Early Detection Initiative: Stratified Screening Strategy for Ireland (LEAD-Ireland) |
| Funding Source: | Health Research Board (HRB) Applied Partnership Awards |
| Role: | Collaborator |
| ID: | APA-2024-001 |
| Date: | 2025 - 2027 |
| Title: | Optimize Ovarian Cancer Primary Prevention Using Decision-Analytic Modeling |
| Funding Source: | Ovarian Cancer Research Alliance (OCRA) |
| Role: | PI |
| ID: | CRDGAI-2025-3-2005 |
| Date: | 2024 - 2028 |
| Title: | Closing the Gap: Advancing Lung Cancer Screening for Individuals Living with Rheumatoid Arthritis |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| ID: | FP00022069 |
| Date: | 2024 - Present |
| Title: | Methods Training for Comparative Effectiveness Research in Cancer |
| Funding Source: | NATIONAL CANCER INSTITUTE |
| Role: | Co-I |
| ID: | R25CA278726 |
| Date: | 2024 - 2029 |
| Title: | Risks and Benefits of Long-Term Osteoporosis Therapy in Women with Breast Cancer |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PI |
| ID: | FP00017894 |
| Date: | 2024 - 2029 |
| Title: | Optimizing Ovarian Cancer Primary Prevention through Mathematical Modeling |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PI |
| ID: | FP00017970 |
| Date: | 2024 - Present |
| Title: | Optimizing Population Selection for Primary (Helicobacter Pylori Screening) and Secondary (endoscopic Screening and Surveillance) Prevention of Gastric Cancer |
| Funding Source: | Baylor College of Medicine |
| Role: | PI |
| ID: | RP220127 |
| Date: | 2024 - 2029 |
| Title: | Personalized risk-based primary prevention of ovarian cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | FP00019524 |
| Date: | 2024 - 2027 |
| Title: | MD Anderson ACCESS Hub for Cancer Screening and Early Detection |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Research Advisory Team Member |
| ID: | GRANT13816531 |
| Date: | 2023 - Present |
| Title: | Cancer Prevention Education: Student Research Experiences |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| ID: | R25CA056452 |
| Date: | 2023 - 2028 |
| Title: | Preventing endometrial cancer through bariatric surgery and long acting reversible contraception |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-PI |
| ID: | FP00018869 |
| Date: | 2023 - 2024 |
| Title: | Lung Moon Shot Expanding Reach |
| Funding Source: | Moon Shot Program |
| Role: | Co-Leader |
| ID: | Lung Moon Shot |
| Date: | 2023 - 2024 |
| Title: | Examining the value of metastasis-directed therapy in oligometastatic disease: A cost and cost-effectiveness analysis |
| Funding Source: | American Society for Therapeutic Radiology and Oncology (ASTRO) |
| Role: | Mentor |
| ID: | FP00018707 |
| Date: | 2023 - 2025 |
| Title: | Personalized Lung Cancer Screening: Project ENGAGE |
| Funding Source: | Andrew Sabin Family Foundation |
| Role: | PI |
| ID: | Andrew Sabin Family Foundation |
| Date: | 2023 - 2027 |
| Title: | Feasibility and Acceptability of Personalized Lung Cancer Screening –Project ENGAGE |
| Funding Source: | The University of Texas MD Anderson Cancer Center Permanent Health Funds |
| Role: | PI |
| ID: | Permanent Health Funds |
| Date: | 2023 - Present |
| Title: | Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Multi-Principal Investigator |
| ID: | RP230213 |
| Date: | 2022 - Present |
| Title: | Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions |
| Funding Source: | The University of British Columbia |
| Role: | Subcontract Principal Investigator |
| ID: | U01CA253858 |
| Date: | 2022 - Present |
| Title: | Clinical Validation Center for Lung Cancer Early Detection |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01CA271888 |
| Date: | 2022 - Present |
| Title: | Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life Expectancy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R37CA271187 |
| Date: | 2022 - 2024 |
| Title: | Development of a risk prediction and natural history models for ovarian cancer |
| Funding Source: | Duncan Family Institute for Cancer Prevention and Risk Assessment Seed-Funding Research Program |
| Role: | PI |
| ID: | DFI Leveraging Seed Funding |
| Date: | 2022 - 2024 |
| Title: | Individualized lung cancer screening through the integration of clinical factors, life expectancy, and biomarkers |
| Funding Source: | Andrew Sabin Family Foundation |
| Role: | PI |
| ID: | Andrew Sabin Family Foundation |
| Date: | 2022 - Present |
| Title: | Understanding and Intercepting Ovarian Carcinogenesis” The BTC Minimal Original Disease (MOD) Ovarian Cancer Team |
| Funding Source: | Break Through Cancer (BTC) |
| Role: | Co-I |
| ID: | FP00015204 |
| Date: | 2022 - 2024 |
| Title: | Establishing the Value of Proton Therapy for Head and Neck Cancer: Assessing Cost-Effectiveness and Financial Toxicity of Therapy |
| Funding Source: | National Association for Proton Therapy (NAPT) |
| Role: | Co-I |
| ID: | FP00015187 |
| Date: | 2021 - 2022 |
| Title: | Acceptability Assessment and Delivery of Personalized Lung Cancer Screening |
| Funding Source: | Cancer Center Support Grant: Risk Detection and Outcomes (RDO) Program |
| Role: | PI |
| ID: | P30CA016672 |
| Date: | 2021 - 2023 |
| Title: | Acceptability of Personalized Lung Cancer Screening |
| Funding Source: | Lung Cancer Research Foundation |
| Role: | PI |
| ID: | LCRF |
| Date: | 2021 - 2022 |
| Title: | Lung Moon Shot Expanding Reach |
| Funding Source: | The University of Texas MD Anderson Cancer Center Moonshot Program |
| Role: | Co-I |
| ID: | Moonshot Program |
| Date: | 2021 - 2022 |
| Title: | Smoking Cessation and Lung Cancer Screening for Dental Patients |
| Funding Source: | The University of Texas Health Science Center (UTHealth)-MD Anderson Cancer Center (MDACC) Population Health Initiative |
| Role: | Investigator |
| ID: | UTH-MDA Population health Initiative Quick Start Award |
| Date: | 2021 - 2026 |
| Title: | CISNET Incubator: Ovarian Cancer |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PI |
| ID: | FP00012740 |
| Date: | 2020 - 2023 |
| Title: | Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions |
| Funding Source: | University of Michigan |
| Role: | PI |
| ID: | U01CA199284 |
| Date: | 2019 - 2020 |
| Title: | Comparative Modeling: Informing Breast Cancer Control Practice and Policy |
| Funding Source: | NIH/NCI |
| Role: | Postdoctoral Fellow |
| ID: | U01 CA199218 |
| Date: | 2019 - 2020 |
| Title: | Administrative Supplement to Controlling Esophageal Cancer: A Collaborative Modeling Approach |
| Funding Source: | NIH/NCI |
| Role: | Consultant |
| ID: | U01 CA199336 |
| Date: | 2017 - 2019 |
| Title: | Personalized, Dynamic Risk-based Lung Cancer Screening |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | F32 CA220961 |
| Date: | 2015 - 2020 |
| Title: | Comparative Modeling of Lung Cancer Prevention and Control Policies |
| Funding Source: | NIH/NCI |
| Role: | Postdoctoral Fellow |
| ID: | U01CA199284 |
Selected Publications
Peer-Reviewed Articles
- Gendarme S, Irajizad E, Long JP, Fahrmann JF, Dennison JB, Ghasemi SM, Dou R, Volk RJ, Meza R, Toumazis I, Canoui-Poitrine F, Hanash SM, Ostrin EJ. Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials. Journal of Thoracic Oncology 20(5):565-576, 2025. e-Pub 2025. PMID: 39798695.
- Nargund, R, Ishizawa, S, Eghbalizarch, M, Yeh, PG, Mousavi Janbeh Saray, SM, Nofal, S, Geng, Y, Cao, P, Ostrin, EJ, Meza, R, Tammemagi, M, Volk, R, Lopez-Olivo, MA, Toumazis, I. Natural history models for lung cancer. Lung Cancer 203, 2025. e-Pub 2025. PMID: 40174386.
- Yeh PG, Haas A, Sun CC, Lu KH, Meyer LA, Toumazis I. Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women. Cancer Prevention Research 18(5):299-306, 2025. e-Pub 2025. PMID: 39930864.
- Nofal S, Ostrin EJ, Zhang J, Wu J, Scheet P, Antonoff MB, Heymach JV, Toumazis I. Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status. Int J Cancer, 2025. PMID: 40249102.
- Tan NQP, Nargund RS, Douglas EE, Lopez-Olivo MA, Resong PJ, Ishizawa S, Nofal S, Krause K, Volk RJ, Toumazis I. Acceptability and perceptions of personalised risk-based cancer screening among health-care professionals and the general public: a systematic review and meta-analysis. Lancet Public Health 10(2):e85-e96, 2025. e-Pub 2025. PMID: 39909697.
- Adjei NN, Haas A, Sun CC, Zhao H, Yeh PG, Giordano SH, Toumazis I, Meyer LA. Health care costs in the United States by demographic characteristics and comorbidity status. Value in Health 28(2):206-214, 2024. e-Pub 2024. PMID: 39532216.
- Irajizad, E, Fahrmann, JF, Toumazis, I, Vykoukal, JV, Dennison, JB, Shen, Y, Do, K, Ostrin, EJ, Feng, Z, Hanash, SM. Biomarker trajectory for earlier detection of lung cancer. EBioMedicine 108, 2024. e-Pub 2024. PMID: 39353277.
- Adjei, Haas, Sun, Zhao, Yeh, Giordano, Toumazis, Meyer. Cost of ovarian cancer by the phase of care in the United States. Am J Obstet Gynecol S0002-9378(24):00846-9, 2024. e-Pub 2024. PMID: 39159781.
- Hemmati, M, Ishizawa, S, Meza, R, Ostrin, EJ, Hanash, S, Antonoff, MB, Schaefer, AJ, Tammemagi, M, Toumazis, I. Benchmarking lung cancer screening programmes with adaptive screening frequency against the optimal screening schedules derived from the ENGAGE framework. EClinicalMedicine 74, 2024. e-Pub 2024. PMID: 39764179.
- Ishizawa S, Niu J, Tammemagi, Irajizad E, Shen Y, Lu KH, Meyer, Toumazis. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. JNCI 00(0):1-9, 2024. e-Pub 2024. PMID: 39038822.
- Ten Haaf K, de Nijs K, Simoni G, Alban A, Cao P, Sun Z, Yong J, Jeon J, Toumazis I, Han SS, Gazelle GS, Kong CY, Plevritis SK, Meza R, de Koning HJ. The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations. Medical Decision Making 44(5):497-511, 2024. e-Pub 2024. PMID: 38738534.
- Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez FR, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Cheng C, Lee JJ, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su D, Fukuoka J, Antonoff MB, Gerber DE, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Spira A, Futreal AP, Reuben A, Zhang J. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Research Square, 2024. e-Pub 2024. PMID: 38798564.
- Salehjahromi, M, Karpinets, T, Sujit, S, Qayati, M, Chen, P, Aminu, M, Saad, MB, Bandyopadhyay, R, Hong, L, Sheshadri, A, Lin, J, Antonoff, MB, Sepesi, B, Ostrin, EJ, Toumazis, I, Huang, P, Cheng, C, Cascone, T, Vokes, N, Behrens, C, Siewerdsen, JH, Hazle, JD, Chang, JY, Zhang, J, Lu, Y, Godoy, M, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Gladish, G, Heymach, JV, Wu, CC, Zhang, J, Wu, J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer : Proof of concept. Cell Reports Medicine 5(3):101463, 2024. e-Pub 2024. PMID: 38471502.
- Nofal, S, Niu, J, Resong, PJ, Jin, J, Merriman, K, Le, X, Katki, HA, Heymach, JV, Antonoff, MB, Ostrin, EJ, Wu, J, Zhang, J, Toumazis, I. Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening. Cancer Med 13(5):E7069, 2024. e-Pub 2024. PMID: 38466021.
- Resong, PJ, Niu, J, Duhon, GF, Foxhall, LE, Shete, S, Volk, R, Toumazis, I. Acceptability of Personalized Lung Cancer Screening Program Among Primary Care Providers. Cancer Prevention Research 17(2):51-57, 2024. e-Pub 2024. PMID: 38212272.
- Maki KG, Tan NQP, Toumazis I, Volk RJ. Prevalence of lung cancer screening in 4 states in the U.S.: A Cross-sectional analysis from the 2021 Behavioral Risk Factor Surveillance System. JAMA Netw Open 6(6):e2319172, 2023. e-Pub 2023. PMID: 37342043.
- Toumazis I, Cao P, de Nijs K, Bastani M, Munshi V, Hemmati M, Ten Haaf K, Jeon J, Tammemägi M, Gazelle GS, Feuer EJ, Kong CY, Meza R, de Koning HJ, Plevritis SK, Han SS. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis. Ann Intern Med 176(3):320-332, 2023. e-Pub 2023. PMID: 36745885.
- Maki KG, Talluri R, Toumazis I, Shete S, Volk RJ. Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility. Cancer Med 12(4):4647-4654, 2023. e-Pub 2023. PMID: 35871312.
- Toumazis I, Erdogan SA, Bastani M, Leung A, Plevritis SK. A Cost-Effectiveness Analysis of Lung Cancer Screening with Low-Dose Computed Tomography and a Diagnostic Biomarker. JNCI Cancer Spectr 5(6), 2021. e-Pub 2021. PMID: 34738073.
- Bastani M, Toumazis I, Hedou' J, Leung A, Plevritis SK. Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. J Am Coll Radiol 18(12):1614-1623, 2021. e-Pub 2021. PMID: 34419477.
- Toumazis I, Alagoz O, Leung A, Plevritis SK. A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. Cancer 127(23):4432-4446, 2021. e-Pub 2021. PMID: 34383299.
- Toumazis I, de Nijs K, Cao P, Bastani M, Munshi V, Ten Haaf K, Jeon J, Gazelle GS, Feuer EJ, de Koning HJ, Meza R, Kong CY, Han SS, Plevritis SK. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncol 7(12):1833-1842, 2021. e-Pub 2021. PMID: 34673885.
- Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 161(1):56-62, 2021. e-Pub 2021. PMID: 33536126.
- Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas DE, Feuer EJ, Plevritis SK, de Koning HJ, Kong CY. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA 325(10):988-997, 2021. e-Pub 2021. PMID: 33687469.
- Han SS, Chow E, Ten Haaf K, Toumazis I, Cao P, Bastani M, Tammemagi M, Jeon J, Feuer EJ, Meza R, Plevritis SK. Disparities of National Lung Cancer Screening Guidelines in the US Population. J Natl Cancer Inst 112(11):1136-1142, 2020. e-Pub 2020. PMID: 32040195.
- Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-Based lung cancer screening: A systematic review. Lung Cancer 147:154-186, 2020. e-Pub 2020. PMID: 32721652.
- Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. J Natl Cancer Inst 112(5):466-479, 2020. e-Pub 2020. PMID: 31566216.
- Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Ann Intern Med 171(11):796-804, 2019. e-Pub 2019. PMID: 31683314.
- Toumazis I, Tsai EB, Erdogan SA, Han SS, Wan W, Leung A, Plevritis SK. Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. JNCI Cancer Spectrum 3(3):pkz035, 2019. e-Pub 2019. PMID: 31942534.
- Tammemägi MC, Ten Haaf K, Toumazis I, Kong CY, Han SS, Jeon J, Commins J, Riley T, Meza R. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial. JAMA Network Open 2(3):e190204, 2019. e-Pub 2019. PMID: 30821827.
- Toumazis I, Kurt M, Toumazi A, Karacosta LG, Kwon C. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy & Practice 2(2):2381468317729650, 2017. e-Pub 2017. PMID: 30288431.
- Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes & Control 28(9):947-958, 2017. e-Pub 2017. PMID: 28702814.
- Toumazis, I, Kwon, C. Worst-case conditional value-At-risk minimization for hazardous materials transportation. Transportation Science 50(4):1174-1187, 2016. e-Pub 2016.
- Toumazis, I, Kwon, C. Routing hazardous materials on time-dependent networks using conditional value-at-risk. Transportation Research Part C: Emerging Technologies 37:73-92, 2013. e-Pub 2013.
Editorials
- Maki KG, Tan NQP, Volk RJ, Toumazis I. Examining Lung Cancer Screening Uptake in the United States: Recent Research and Limitations of Public-Use Data. Cancer Epidemiol Biomarkers Prev. Cancer Epidemiol Biomarkers Prev 34(1):9-11, 2025. PMID: 39780617.
Abstracts
- Salehjahromi M, Hong L, Li H, Kitsel Y, Godoy M, Wu CC, Antonoff M, Toumazis I, Ostrin EJ, Heeke S, Vokes NI, Le X, Vaporciyan AA, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting lung cancer risk with CT radiomics: implications for immunoprevention. Society for Immunotherapy of Cancer's 39th Annual Meeting 12, 2024. e-Pub 2024.
- Adjei N, Yeh PG, Haas A, Zhao H, Stone R, Roche KL, Lu K, Sun CC, Toumazis I, Meyer LA. Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: A cost-effectiveness analysis. Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer and 2024 Winter Meeting 190(Supplement 1):S26-S27, 2024. e-Pub 2024.
- Ishizawa S, Niu J, Tammemagi M, Irajizad E, Shen Y, Lu K, Meyer LA, Toumazis I. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. INFORMS Annual Meeting 2024, 2024. e-Pub 2024.
- Maki KG, Tan NQP, Volk RJ, Toumazis I. Lung Cancer Screening Eligibility and Use in the US: A Cross-Sectional Analysis of 2022 Behavioral Risk Factor Surveillance System Data. ISPOR 2024 international conference, HEOR: A Transformative Force for Whole Health 27(6):S167, 2024. e-Pub 2024.
- Li H, Qin K, Zhang Z, Hong L, Wu CC, Barco Godoy MC, Antonoff M, Ostrin EJ, Toumazis I, Gibbons DL, Heymach J, Lee J, Wu J, Zhang J. Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival. 2023 ASCO Annual Meeting I 41(16), 2023. e-Pub 2023.
- Resong P, Niu J, Duhon G, Foxhall L, Shete S, Volk RJ, Toumazis I. Lung cancer screening status and acceptability of a personalized approach in Texas. 2023 ASCO Annual Meeting I 41(16), 2023. e-Pub 2023.
- Yeh, Toumazis, Sun, Lu, Meyer. Disparities in uptake of levonorgestrel-releasing intrauterine system (LNG-IUS): implications for uterine cancer primary prevention. AACR Annual Meeting 2023 83(7):5769, 2023. e-Pub 2023.
- Hemmati M, Toumazis I. The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program. Abstracts from the 2022 World Conference on Lung Cancer 17(9):S178-S179, 2022. e-Pub 2022.
- Bastani M, Toumazis I, Plevritis SK, Hedou J, Leung A. Evaluation of Alternative Diagnostic Follow-Up Intervals for Lung-RADS Criteria on the Effectiveness of Lung Cancer Screening. World Conference on Lung Cancer 16(3):S150-S151, 2021. e-Pub 2021.
- Han SS, Chow E, ten Haaf K, Toumazis I, Cao P, Bastani M, Tammemagi M, Jeon J, Feuer EJ, Meza R, Plevritis SK. Disparities of National Lung Cancer Screening Guidelines in the US Population. World Conference on Lung Cancer, 2019. e-Pub 2019.
- Toumazis I, Alagoz O, Leung A, Plevritis SK. Individualized Risk-Based Lung Cancer Screening Incorporating Past Screening Findings and Changes in Smoking Behaviors. World Conference on Lung Cancer 14(10):S792, 2019. e-Pub 2019.
- Toumazis I, Kurt M, Karacosta LG, Toumazi A, Kwon C, Goldstein DA. Assessing the role of sequencing up to three lines of chemotherapy in metastatic colorectal cancer treatment: A cost-effectiveness analysis. The 37th Annual Meeting of the Society of Medical Decision Making, 2015. e-Pub 2015.
- Toumazis I, Kurt M, Karacosta LG, Toumazi A, Kwon C, Goldstein DA. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. MSOM Healthcare Special Interest Group Meeting, 2015. e-Pub 2015.
- Toumazis I, Kurt M, Ozaltin O, Denton BT, Shah ND. Eliciting cholesterol management guidelines' valuation of future life. The 36th Annual Meeting of the Society for Medical Decision Making, 2014. e-Pub 2014.
Book Chapters
- Toumazis I, Kwon C, Batta R. Value-at-risk and Conditional Value-at-Risk Minimization for Hazardous Materials Routing. In: Handbook of OR/MS Models in Hazardous Materials Transportation (Eds.: R. Batta and C. Kwon. Springer, 2013.
Patient Reviews
CV information above last modified July 10, 2025